Lichtenberg Frank R
Graduate School of Business, Columbia University, National Bureau of Economic Research, 614 Uris Hall, 3022 Broadway, New York, NY 10027, USA.
Int J Health Care Finance Econ. 2005 Mar;5(1):47-73. doi: 10.1007/s10754-005-6601-7.
We perform an econometric analysis of the effect of new drug launches on longevity, using data from the IMS Health Drug Launches database and the WHO Mortality Database. Under conservative assumptions, our estimates imply that the average annual increase in life expectancy of the entire population resulting from new drug launches is about one week, and that the incremental cost effectiveness ratio (new drug expenditure per person per year divided by the increase in life-years per person per year attributable to new drug launches) is about $6750--far lower than most estimates of the value of a statistical life-year.
我们利用艾美仕市场研究公司（IMS Health）药品上市数据库和世界卫生组织（WHO）死亡率数据库的数据，对新药上市对寿命的影响进行了计量经济学分析。在保守假设下，我们的估计表明，新药上市使整个人口预期寿命的年平均增加约为一周，增量成本效益比（每人每年的新药支出除以新药上市导致的每人每年生命年数的增加）约为6750美元，远低于大多数统计生命年价值的估计。
